- Home
- CDNA vs PCN Comparison
CDNA vs PCN Comparison
Compare CDNA & PCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDNA
- PCN
- Stock Information
- Founded
- CDNA 1998
- PCN 2001
- Country
- CDNA United States
- PCN United States
- Employees
- CDNA N/A
- PCN N/A
- Industry
- CDNA Medical Specialities
- PCN Investment Managers
- Sector
- CDNA Health Care
- PCN Finance
- Exchange
- CDNA Nasdaq
- PCN Nasdaq
- Market Cap
- CDNA 712.2M
- PCN 837.5M
- IPO Year
- CDNA 2014
- PCN N/A
- Fundamental
- Price
- CDNA $13.82
- PCN $13.11
- Analyst Decision
- CDNA Buy
- PCN
- Analyst Count
- CDNA 7
- PCN 0
- Target Price
- CDNA $27.67
- PCN N/A
- AVG Volume (30 Days)
- CDNA 1.5M
- PCN 218.7K
- Earning Date
- CDNA 11-03-2025
- PCN 01-01-0001
- Dividend Yield
- CDNA N/A
- PCN 9.73%
- EPS Growth
- CDNA N/A
- PCN N/A
- EPS
- CDNA 1.00
- PCN N/A
- Revenue
- CDNA $340,826,000.00
- PCN N/A
- Revenue This Year
- CDNA $13.02
- PCN N/A
- Revenue Next Year
- CDNA $12.85
- PCN N/A
- P/E Ratio
- CDNA $13.85
- PCN N/A
- Revenue Growth
- CDNA 14.72
- PCN N/A
- 52 Week Low
- CDNA $10.96
- PCN $10.70
- 52 Week High
- CDNA $32.97
- PCN $14.48
- Technical
- Relative Strength Index (RSI)
- CDNA 54.96
- PCN 82.79
- Support Level
- CDNA $12.37
- PCN $12.96
- Resistance Level
- CDNA $14.20
- PCN $12.93
- Average True Range (ATR)
- CDNA 0.73
- PCN 0.07
- MACD
- CDNA 0.27
- PCN 0.03
- Stochastic Oscillator
- CDNA 87.02
- PCN 94.65
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
About PCN Pimco Corporate & Income Strategy Fund
PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.